EDITAS MEDICINE, INC. Net Income
EDITAS MEDICINE, INC. (EDIT) reported Net Income of -$18.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-05
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$18.23M.
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$24.98M.
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$5.62M.
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$25.12M.
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for fiscal 2022 was -$220.43M.
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for fiscal 2021 was -$192.50M.
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for fiscal 2020 was -$115.98M.
- EDITAS MEDICINE, INC. net income (loss) attributable to parent for fiscal 2019 was -$133.75M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.23M 10-Q · filed 2026-08-05 | -$43.21M 10-Q · filed 2026-08-05 | -$48.83M derived: sum of 3 quarters · filed 2026-08-05 | -$73.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$24.98M 10-Q · filed 2026-08-05 | -$30.60M derived: sum of 2 quarters · filed 2026-08-05 | -$55.72M derived: sum of 3 quarters · filed 2026-08-05 | -$108.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$5.62M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$30.74M derived: sum of 2 quarters · filed 2026-04-28 | -$83.97M derived: sum of 3 quarters · filed 2026-08-05 | -$160.06M DEF 14A · filed 2026-04-28 |
| 2025-09-30 | -$25.12M 10-Q · filed 2025-11-10 | -$78.35M derived: sum of 2 quarters · filed 2026-08-05 | -$154.44M 10-Q · filed 2025-11-10 | -$199.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$53.23M 10-Q · filed 2026-08-05 | -$129.32M 10-Q · filed 2026-08-05 | -$174.72M derived: sum of 3 quarters · filed 2026-08-05 | -$236.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$76.09M 10-Q · filed 2026-08-05 | -$121.48M derived: sum of 2 quarters · filed 2026-08-05 | -$183.62M derived: sum of 3 quarters · filed 2026-08-05 | -$251.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2024-12-31 | -$45.40M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$107.54M derived: sum of 2 quarters · filed 2026-04-28 | -$175.14M derived: sum of 3 quarters · filed 2026-04-28 | -$237.09M DEF 14A · filed 2026-04-28 |
| 2024-09-30 | -$62.14M 10-Q · filed 2025-11-10 | -$129.75M derived: sum of 2 quarters · filed 2025-11-10 | -$191.70M 10-Q · filed 2025-11-10 | -$210.57M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-06-30 | -$67.61M 10-Q · filed 2025-11-10 | -$129.56M 10-Q · filed 2025-08-12 | -$148.43M derived: sum of 3 quarters · filed 2026-04-28 | -$193.45M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-03-31 | -$61.95M 10-Q · filed 2025-11-10 | -$80.82M derived: sum of 2 quarters · filed 2026-04-28 | -$125.84M derived: sum of 3 quarters · filed 2026-04-28 | -$166.13M derived: sum of 4 quarters · filed 2026-04-28 |
| 2023-12-31 | -$18.87M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$63.89M derived: sum of 2 quarters · filed 2026-04-28 | -$104.18M derived: sum of 3 quarters · filed 2026-04-28 | -$153.22M DEF 14A · filed 2026-04-28 |
| 2023-09-30 | -$45.02M 10-Q · filed 2024-11-04 | -$85.31M derived: sum of 2 quarters · filed 2024-11-04 | -$134.34M 10-Q · filed 2024-11-04 | -$195.08M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | -$40.29M 10-Q · filed 2024-11-04 | -$89.33M 10-Q · filed 2024-08-07 | -$150.06M derived: sum of 3 quarters · filed 2025-03-05 | -$205.79M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | -$49.04M 10-Q · filed 2024-11-04 | -$109.77M derived: sum of 2 quarters · filed 2025-03-05 | -$165.50M derived: sum of 3 quarters · filed 2025-03-05 | -$218.95M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | -$60.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$116.46M derived: sum of 2 quarters · filed 2025-03-05 | -$169.92M derived: sum of 3 quarters · filed 2025-03-05 | -$220.43M 10-K · filed 2025-03-05 |
| 2022-09-30 | -$55.73M 10-Q · filed 2023-11-03 | -$109.18M derived: sum of 2 quarters · filed 2023-11-03 | -$159.69M 10-Q · filed 2023-11-03 | -$201.13M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$53.45M 10-Q · filed 2023-11-03 | -$103.97M 10-Q · filed 2023-08-02 | -$145.40M derived: sum of 3 quarters · filed 2024-02-28 | -$184.49M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$50.52M 10-Q · filed 2023-11-03 | -$91.95M derived: sum of 2 quarters · filed 2024-02-28 | -$131.03M derived: sum of 3 quarters · filed 2024-02-28 | -$186.29M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$41.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$80.52M derived: sum of 2 quarters · filed 2024-02-28 | -$135.77M derived: sum of 3 quarters · filed 2024-02-28 | -$192.50M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$39.08M 10-Q · filed 2022-11-02 | -$94.34M derived: sum of 2 quarters · filed 2022-11-02 | -$151.07M 10-Q · filed 2022-11-02 | -$213.56M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | -$55.26M 10-Q · filed 2022-11-02 | -$111.98M 10-Q · filed 2022-08-03 | -$174.48M derived: sum of 3 quarters · filed 2022-11-02 | -$166.66M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-03-31 | -$56.73M 10-Q · filed 2022-11-02 | -$119.23M derived: sum of 2 quarters · filed 2022-11-02 | -$111.41M derived: sum of 3 quarters · filed 2022-11-02 | -$134.98M derived: sum of 4 quarters · filed 2022-11-02 |
| 2020-12-31 | -$62.50M 10-K · filed 2021-02-26 | -$54.68M derived: sum of 2 quarters · filed 2021-11-09 | -$78.25M derived: sum of 3 quarters · filed 2021-11-09 | -$115.98M 10-K · filed 2023-02-22 |
| 2020-09-30 | $7.82M 10-Q · filed 2021-11-09 | -$15.75M derived: sum of 2 quarters · filed 2021-11-09 | -$53.48M 10-Q · filed 2021-11-09 | -$91.25M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$23.57M 10-Q · filed 2021-11-09 | -$61.30M 10-Q · filed 2021-08-05 | -$99.07M derived: sum of 3 quarters · filed 2021-11-09 | -$132.01M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-03-31 | -$37.72M 10-Q · filed 2021-11-09 | -$75.49M derived: sum of 2 quarters · filed 2021-11-09 | -$108.44M derived: sum of 3 quarters · filed 2021-11-09 | -$142.22M derived: sum of 4 quarters · filed 2021-11-09 |
| 2019-12-31 | -$37.77M 10-K · filed 2021-02-26 | -$70.71M derived: sum of 2 quarters · filed 2021-02-26 | -$104.50M derived: sum of 3 quarters · filed 2021-02-26 | -$133.75M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$32.94M 10-K · filed 2021-02-26 | -$66.73M derived: sum of 2 quarters · filed 2021-02-26 | -$95.98M 10-Q · filed 2020-11-06 | -$121.03M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$33.79M 10-K · filed 2021-02-26 | -$63.03M 10-Q · filed 2020-08-07 | -$88.09M derived: sum of 3 quarters · filed 2021-02-26 | -$103.33M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$29.25M 10-K · filed 2021-02-26 | -$54.30M derived: sum of 2 quarters · filed 2021-02-26 | -$69.54M derived: sum of 3 quarters · filed 2021-02-26 | -$108.26M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$25.05M 10-K · filed 2020-02-26 | -$40.29M derived: sum of 2 quarters · filed 2020-02-26 | -$79.02M derived: sum of 3 quarters · filed 2020-02-26 | -$109.95M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$15.24M 10-K · filed 2020-02-26 | -$53.96M derived: sum of 2 quarters · filed 2020-02-26 | -$84.90M 10-Q · filed 2019-11-12 | -$121.09M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$38.72M 10-K · filed 2020-02-26 | -$69.66M 10-Q · filed 2019-08-07 | -$105.85M derived: sum of 3 quarters · filed 2020-02-26 | -$132.45M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$30.94M 10-K · filed 2020-02-26 | -$67.13M derived: sum of 2 quarters · filed 2020-02-26 | -$93.73M derived: sum of 3 quarters · filed 2020-02-26 | -$120.17M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | -$36.19M 10-K · filed 2019-03-01 | -$62.79M derived: sum of 2 quarters · filed 2019-03-01 | -$89.23M derived: sum of 3 quarters · filed 2019-03-01 | -$120.32M 10-K · filed 2020-02-26 |
| 2017-09-30 | -$26.60M 10-K · filed 2019-03-01 | -$53.04M derived: sum of 2 quarters · filed 2019-03-01 | -$84.14M 10-Q · filed 2018-11-08 | -$123.51M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$26.44M 10-K · filed 2019-03-01 | -$57.54M 10-Q · filed 2018-08-07 | -$96.91M derived: sum of 3 quarters · filed 2019-03-01 | -$117.93M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$31.10M 10-K · filed 2019-03-01 | -$70.47M derived: sum of 2 quarters · filed 2019-03-01 | -$91.49M derived: sum of 3 quarters · filed 2019-03-01 | -$110.53M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | -$39.38M 10-K · filed 2018-03-08 | -$60.40M derived: sum of 2 quarters · filed 2018-03-08 | -$79.44M derived: sum of 3 quarters · filed 2018-03-08 | -$97.18M 10-K · filed 2019-03-01 |
| 2016-09-30 | -$21.02M 10-K · filed 2018-03-08 | -$40.06M derived: sum of 2 quarters · filed 2018-03-08 | -$57.81M 10-Q · filed 2017-11-08 | -$70.44M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$19.04M 10-K · filed 2018-03-08 | -$36.79M 10-Q · filed 2017-08-09 | -$49.42M derived: sum of 3 quarters · filed 2018-03-08 | -$56.83M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$17.75M 10-K · filed 2018-03-08 | -$30.38M derived: sum of 2 quarters · filed 2018-03-08 | -$37.78M derived: sum of 3 quarters · filed 2018-03-08 | -$85.35M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$12.63M 10-K · filed 2017-03-03 | -$20.04M derived: sum of 2 quarters · filed 2017-03-03 | -$67.61M derived: sum of 3 quarters · filed 2017-03-03 | -$72.90M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$7.41M 10-K · filed 2017-03-03 | -$54.98M derived: sum of 2 quarters · filed 2017-03-03 | -$60.27M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$47.57M 10-K · filed 2017-03-03 | -$52.86M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | -$5.29M 10-K · filed 2017-03-03 | |||
| 2014-12-31 | -$13.69M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |